Furthermore, CD31 staining showed that Liensinine combined with immunotherapy significantly reduced tumor vascular density, a reduction not observed with radiotherapy alone, suggesting that Liensinine influences tumor vasculature in a way that enhances immunotherapy efficacy (Fig. 7F). This evidence concerns the gene PECAM1 and neoplasm.